## Amendments to the Claims

## **Listing of the Claims:**

Claim 1 (canceled)

Claim 2 (currently amended): The <u>use-method</u> according to claim <u>410</u>, wherein the pulmonary hypertension is selected from primary pulmonary hypertension or secondary pulmonary hypertension.

Claim 3 (currently amended): The <u>use-method</u> according to claim <u>1-10</u> wherein a daily dose of 100 to 1000 mg of COMPOUND I of the formula I is administered to an adult human.

Claim 4 (currently amended): The <u>use-method</u> according to claim 3 wherein the daily dose is administered for a period exceeding three months.

Claim 5 (currently amended): The <u>use-method</u> according to <u>any-one of claims 1 to 4 claim 10</u> wherein the pulmonary hypertension is not caused or accompanied by pulmonary fibrosis.

Claim 6 (currently amended): The <u>use method</u> according to <u>anyone of claims 1 or 4 claim 10</u> wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine of the formula I is in the form of a pharmaceutically acceptable acid addition salt.

Claim 7 (currently amended): The <u>use-method</u> according to claim 6 wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine of the formula I is in the form of the monomethanesulfonate salt.

Claim 8 (currently amended): Use of a A combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine (designated hereinafter as COMPOUND I) and (b) at least one compound selected from the group comprising calcium channel antagonists, anticoagulants, endothelin receptor blockers, angiotensin-converting enzyme inhibitors, diuretics, and phosphodiesterease inhibitors for the manufacture of a medicament for the treatment of pulmonary hypertension.

Claim 9 (currently amended): Use of a <u>The</u> combination according to claim 8 wherein (b) is at least one compound selected from the group comprising nifedipine, diltiazem, enalapril prostacyclin, adenosine, inhaled nitric oxide, warfarin, digoxin, bosentan, Viagra, and norepinephrine.

Claim 10 (original): A method of treating humans suffering from pulmonary hypertension which comprises administering to a said human in need of such treatment a dose, effective against pulmonary hypertension, of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine of the formula I

(I)

or a pharmaceutically acceptable salt thereof.